Phase 2 open-label extension (OLE) study of patisiran for the treatment of hereditary ATTR (hATTR) amyloidosis: 24-month safety and efficacy in subgroup of patients with cardiac involvement

Phase 2 open-label extension (OLE) study of patisiran for the treatment of hereditary ATTR (hATTR) amyloidosis : 24-month safety and efficacy in subgroup of patients with cardiac involvement

Adams, D. (author)

Coelho, T. (author)

Conceicao, I. (author)

Cruz, M. Waddington (author)

Schmidt, H. (author)

Buades, J. (author)

Campistol, J. (author)

Pouget, J. (author)

Berk, J. L. (author)

Ziyadeh, N. (author)

Partisano, A. M. (author)

Sweetser, M. (author)

Chen, J. (author)

Gollob, J. (author)

(creator_code:org_t)

WILEY, 2017
2017
English.
In: European Journal of Heart Failure. - : WILEY. - 1388-9842 .- 1879-0844. ; 19:Suppl: 1, s. 19-19

Subject headings

By the author/editor: Adams, D.; Coelho, T.; Conceicao, I.; Cruz, M. Wadding ...; Schmidt, H.; Buades, J.; show more...; Campistol, J.; Pouget, J.; Berk, J. L.; Ziyadeh, N.; Partisano, A. M.; Sweetser, M.; Chen, J.; Gollob, J.; Suhr, Ole; show less...

About the subject

MEDICAL AND HEALTH SCIENCES: MEDICAL AND HEAL ...; and Health Sciences; and Public Health Gl ...

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.